Literature DB >> 22929941

Diagnosis of dementia--automatic quantification of brain structures.

Knut Engedal1, Anne Brækhus, Ole A Andreassen, Per Hj Nakstad.   

Abstract

BACKGROUND: The aim of the present study was to examine the usefulness of a fully automatic quantification of brain structures by means of magnetic resonance imaging (MRI) for diagnosing dementia of the Alzheimer's type (DAT). MATERIAL AND
METHOD: MRI scans of the brains of 122 patients, referred to a memory clinic, were analysed using Neuroquant® software, which quantifies the volume of various brain structures. Clinical diagnoses were made by two doctors without knowledge of the MRI results. We performed Receiver Operating Characteristic analyses and calculated the area under the curve (AUC). A value of 1 means that all ill patients have been diagnosed as diseased and no patient has been falsely diagnosed as diseased.
RESULTS: The mean age of the patients was 67.2 years (SD 10.5 years), 60 % were men, 63 had DAT, 24 had another type of dementia, 25 had mild cognitive impairment (MCI) and ten had subjective cognitive impairment (SCI). In the comparison between DAT patients and patients with SCI or MCI, seven of eleven volumes were significantly larger than AUC 0.5. Positive and negative likelihood ratios were less than 5 and more than 0.2, respectively, for the best limit values of the volumes. Apart from the cerebellum (AUC 0.67), none of the brain structures was significantly different from AUC 0.5 in patients with dementia conditions other than dementia Alzheimer's type.
INTERPRETATION: MRI scans with Neuroquant analyses cannot be used alone to distinguish between persons with dementia of Alzheimer's type and persons without dementia.

Entities:  

Mesh:

Year:  2012        PMID: 22929941     DOI: 10.4045/tidsskr.12.0148

Source DB:  PubMed          Journal:  Tidsskr Nor Laegeforen        ISSN: 0029-2001


  4 in total

1.  Magnetic Resonance Volumetry: Prediction of Subjective Memory Complaints and Mild Cognitive Impairment, and Associations with Genetic and Cardiovascular Risk Factors.

Authors:  Sigbjørn Rogne; Torgil Vangberg; Petter Eldevik; Gry Wikran; Ellisiv B Mathiesen; Henrik Schirmer
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2016-11-25

Review 2.  Updated Review of the Evidence Supporting the Medical and Legal Use of NeuroQuant® and NeuroGage® in Patients With Traumatic Brain Injury.

Authors:  David E Ross; John Seabaugh; Jan M Seabaugh; Justis Barcelona; Daniel Seabaugh; Katherine Wright; Lee Norwind; Zachary King; Travis J Graham; Joseph Baker; Tanner Lewis
Journal:  Front Hum Neurosci       Date:  2022-04-08       Impact factor: 3.473

3.  Normal Vitamin Levels and Nutritional Indices in Alzheimer's Disease Patients with Mild Cognitive Impairment or Dementia with Normal Body Mass Indexes.

Authors:  Ingun Ulstein; Thomas Bøhmer
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Sectoral segmentation of retinal amyloid imaging in subjects with cognitive decline.

Authors:  Oana M Dumitrascu; Patrick D Lyden; Tania Torbati; Julia Sheyn; Ayesha Sherzai; Dean Sherzai; Dale S Sherman; Ryan Rosenberry; Susan Cheng; Kenneth O Johnson; Alan D Czeszynski; Steven Verdooner; Sally Frautschy; Keith L Black; Yosef Koronyo; Maya Koronyo-Hamaoui
Journal:  Alzheimers Dement (Amst)       Date:  2020-09-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.